Resmed Inc (RMD) Receives a Hold from BMO Capital
BMO Capital analyst Joanne Wuensch maintained a Hold rating on Resmed Inc (NYSE: RMD) today and set a price target of $109. The company’s shares opened today at $100.94.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 12.6% and a 69.8% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Wright Medical Group, and Irhythm Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed Inc with a $94.50 average price target, which is a -6.4% downside from current levels. In a report released today, Needham also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $116.64 and a one-year low of $81.01. Currently, Resmed Inc has an average volume of 683.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.